Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: AstraZeneca; Brigham and Women's Hospital; Massachusetts General Hospital
• Treatments: Tamoxifen

Criteria

Inclusion Criteria:

• Females diagnosed with Hodgkin's Disease at age < 35 years

• > 5 years from mantle or chest radiation

• Current age > 30 years

• Has completed childbearing

• Willingness to discontinue use of oral contraceptives or other hormonal contraception for duration of the study

Exclusion Criteria:

• History of secondary malignancy after Hodgkin's disease, except thyroid cancer of basal cell cancer

• Recurrence of Hodgkin's disease in the 5 years before study entry

• Current participation in any other cancer prevention study

• Current or prior use of tamoxifen

• Current use of coumadin

• History of deep venous thrombosis, pulmonary embolism, or a condition known to be associated with hypercoagulability

• History of cerebrovascular accident

• History of macular degeneration

• Current use of chemotherapy for benign disease